OOIR: Observatory of International Research

Papers

(The H4-Index of Rheumatology is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Granulomatosis with polyangiitis presenting as obstructive uropathy and vasculitic myopathy	175
Comment on: Muscle involvement in systemic lupus erythematosus: multimodal ultrasound assessment and relationship with physical performance	84
COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study	83
Comment on: Switching from prednisolone to dexamethasone in difficult-to-treat rheumatoid arthritis	77
Comment on: Increased risk of osteoporosis and femoral neck fractures in patients with familial Mediterranean fever—a large retrospective cohort study	67
Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists: reply	62
Boxer’s shape, an unusual finding in nailfold capillaroscopy	59
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis: reply	58
Correction to: Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis	58
Prosthetic infections following tocilizumab treatment in patients with rheumatoid arthritis	57
Comment on: Predictors of lack of response to methotrexate in juvenile idiopathic arthritis–associated uveitis	56
E44 Differences of hematological abnormalities between COVID-19 infection and multisystemic inflammatory syndrome (MIS-C)	54
P011 Rituximab and COVID-19 vaccines; are they fit for purpose?	53
29 Juvenile idiopathic arthritis and osteogenesis imperfecta: an exceptional association	52
P042 Using a Genetic PROBability tool (G-PROB) to aid diagnosis of patients with inflammatory arthritis: results from the Norfolk Arthritis Register	52
67 Double impact: hypophosphatemic rickets and vitamin D intoxication	49
P114 Medication adherence to b/tsDMARDS remains sub-optimal in refractory rheumatoid arthritis	48
P173 The positive utility of PSAID-12 score in remote monitoring and the impact of gender and treatment on patient reported outcomes in psoriatic arthritis	47
E046 Lytic lesions; metastatic disease or gout?	45
P073 Functional investigation of Osteoarthritis-associated non-coding variants using CRISPR/Cas9-mediated perturbation of active enhancer regions	44
P058 Pneumocystis Jirovecii Infection in autoimmune inflammatory rheumatic diseases in Oxford	44
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment	43
P041 Successful reversal of microvascular damage with standard therapy in a case of dermatomyositis overlap syndrome	43
E051 Audit of the management of patients over 75 with osteoporotic fragility fractures in primary care	42
P043 Income-Related Health Inequality and Osteoarthritis Intervention Outcomes: a Cohort Study	41

P110 Challenges of meeting NICE guidance for rheumatoid arthritis in the modern era: a service audit	40
E078 Inflammation modifies the effect of rheumatoid arthritis in overall mortality among females	40
26 Kawasaki’s disease vs systemic juvenile idiopathic arthritis, a diagnostic dilemma	40
P004 Empowering the reproductive choices of patients with rheumatic disease: using the BSR 2022 pregnancy guidelines audit tool to evaluate pre-conception medication advice	38
OA12 An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years	38
Comment on: Associations between loneliness, disease activity, and disease impact in inflammatory arthritis: a nationwide cross-sectional study among more than 12 000 patients	38
P004 Temporal and regional variation in the initiation of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study	37
P174 Identifying patterns of fatigue across flares in patients with axial spondyloarthritis	37
P133 Experiences of people with digital ulcers through filmed interviews	37
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies	37
Impaired humoral and T helper cell responses to toxic shock syndrome toxin-1 (TSST-1) in granulomatosis with polyangiitis	36
Sensorineural hearing loss in anti-interleukin-1 treated CAPS patients: risk factors and real-life barriers—an observational study	36
P104 The role of occupational therapy for the self-management of rheumatoid arthritis: a mixed methods systematic review	36
Enhancing diagnosis of gout with deep learning in dual-energy computed tomography: a retrospective analysis of crystal and artefact differentiation	36
54 Kawasaki disease: experience in a general paediatric department of the CHU de Annaba Algeria	36